Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis (NCT06397911)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
Who can join: Review the eligibility criteria below.
Location: First OC Dermatology — Fountain Valley, California
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- First OC Dermatology — Fountain Valley, California
- Center for Dermatology Clinical Research, Inc. — Fremont, California
- California Allergy and Asthma Medical Group — Los Angeles, California
- University of California, Davis Health, Department of Dermatology — Sacramento, California
- UT Health Science Houston — Bellaire, Texas
- Center for Clinical Studies — Webster, Texas
- Kaohsiung Chang Gung Memorial Hospital — Kaohsiung City,
- Kaohsiung Veterans General Hospital — Kaohsiung City,
- Linkou Chang Gung Memorial Hospital — New Taipei City,
- Taipei Medical University-Shuang Ho Hospital — New Taipei City,
- China Medical University Hospital — Taichung,
- National Cheng Kung University Hospital — Tainan,
- National Taiwan University Hospital — Taipei,
- Taipei Mackay Memorial Hospital — Taipei,
- Taipei Veterans General Hospital — Taipei,
- Tri-Service General Hospital — Taipei,
📞 Contact the Study Coordinator
Phone: (022) 703-1098
Email: jessica.ho@onenessbio.com.tw
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.